fullout
MADRID (AFX) - Zeltia SA unit PharmaMar SA said new studies in sarcomas confirm the therapeutic impact of its lead compound Yondelis in soft tissue sarcoma (STS) patients.
In a statement, Zeltia said the new data will be presented at the 12th Annual Meeting of the Connective Tissue Oncology Society (CTOS) being held in Venice Nov 2-4.
'The new data on Yondelis provides additional proof of its effects on patients with STS...Now it is time to investigate further into the possible therapeutic impact of the drug in the treatment of other cancers with a similar molecular signature.' afxmadrid@afxnews.com jdy/tw COPYRIGHT Copyright AFX News Limited 2006. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
© 2006 AFX News
